Both deletions and amplifications were especially notable among prostate cancers, where increasing expression of CDK19 and CDK8 has been shown to be associated with carcinogenesis and acquisition of the largely incurable CRPC phenotype [8]. The gene discussed is CDK8; the disease is prostate carcinoma.